Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP476407.RAQtQt4_8BjnpGKUNlwpoMEp3XyiVlJPa6cH8vQ7sZPtw130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP476407.RAQtQt4_8BjnpGKUNlwpoMEp3XyiVlJPa6cH8vQ7sZPtw130_assertion type Assertion NP476407.RAQtQt4_8BjnpGKUNlwpoMEp3XyiVlJPa6cH8vQ7sZPtw130_head.
- NP476407.RAQtQt4_8BjnpGKUNlwpoMEp3XyiVlJPa6cH8vQ7sZPtw130_assertion description "[In conclusion, a 24-month course of treatment with 6 MU IFN-alpha2b was well tolerated by most patients, led to sustained suppression of HBV in one third, and attenuated hepatitis in 81% of patients.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP476407.RAQtQt4_8BjnpGKUNlwpoMEp3XyiVlJPa6cH8vQ7sZPtw130_provenance.
- NP476407.RAQtQt4_8BjnpGKUNlwpoMEp3XyiVlJPa6cH8vQ7sZPtw130_assertion evidence source_evidence_literature NP476407.RAQtQt4_8BjnpGKUNlwpoMEp3XyiVlJPa6cH8vQ7sZPtw130_provenance.
- NP476407.RAQtQt4_8BjnpGKUNlwpoMEp3XyiVlJPa6cH8vQ7sZPtw130_assertion SIO_000772 9398007 NP476407.RAQtQt4_8BjnpGKUNlwpoMEp3XyiVlJPa6cH8vQ7sZPtw130_provenance.
- NP476407.RAQtQt4_8BjnpGKUNlwpoMEp3XyiVlJPa6cH8vQ7sZPtw130_assertion wasDerivedFrom befree-20150227 NP476407.RAQtQt4_8BjnpGKUNlwpoMEp3XyiVlJPa6cH8vQ7sZPtw130_provenance.
- NP476407.RAQtQt4_8BjnpGKUNlwpoMEp3XyiVlJPa6cH8vQ7sZPtw130_assertion wasGeneratedBy ECO_0000203 NP476407.RAQtQt4_8BjnpGKUNlwpoMEp3XyiVlJPa6cH8vQ7sZPtw130_provenance.